| Ironwood Pharmaceuticals Announces Participation in J.P. Morgan Biotech CEO/CFO Conference Call (Business Wire) CAMBRIDGE, Mass.----Ironwood Pharmaceuticals, Inc. today announced it will participate in the J.P. Morgan Biotech: CEO/CFO Conference Call Series at 10:00 a.m. Eastern Time on Friday, May 28, 2010. us.rd.yahoo.com |
PPD Names Mike Wilkinson as Executive Vice President and Chief Information Officer, Paul Colvin as Executive Vice President of Global Clinical Development (Business Wire) WILMINGTON, N.C.----PPD, Inc. today announced it has appointed Mike Wilkinson, Ph.D., as executive vice president and chief information officer and Paul Colvin as executive vice president of global clinical development effective June 30. us.rd.yahoo.com |
Did the Market Overreact to Curis's Latest Setback? EP Vantage submits:Curis (CRIS) was punished on the stock market for the second time in as many months Monday after releasing a disappointingly opaque announcement on a phase II trial of its lead candidate, the hedgehog pathway inhibitor GDC-0449, in ovarian cancer. In what could politely be described as a vague statement, Curis said further analyses are needed before a decision on continuing development can be taken. This has prompted investors to conclude that study has, or will, fail and comes at an unsteady time for Curis, following so soon after the drug’s failure in colon cancer (CRC) in June (Prickly response as Curis' hedgehog candidate disappoints, June 17, 2010). However, it is worth bearing in mind that Roche (RHHBY.PK) is pitting this first-in-class candidate in numerous tumor types, and phase II data from the most promising setting, basal cell carcinoma (BCC), has yet to be seen. The drug’s potential might seem to be narrowing, and it certainly remains high risk, but it is too early to completely write it off, something that the stock market appears to be doing.Complete Story » seekingalpha.com |
Court Won't Reconsider Ruling on Drug-Patent Deals A federal appeals court declined to reconsider its April ruling that upheld the legality of pharmaceutical-patent settlements that can delay the introduction of generic drugs. online.wsj.com |
Sanofi-Aventis Enters Collaboration With Harvard in Effort to Externalize R&D The Burrill Report submits: By Daniel S. Levine Sanofi-Aventis (SNY) has entered into a research collaboration with Harvard University in the hopes of accelerating discoveries from the lab to the clinic. The translational research collaboration extends across several therapeutic areas including cancer, diabetes and inflammation. Under the collaboration, Harvard University investigators will propose research projects across a wide range of areas. The funded projects will be selected by a Joint Scientific Steering Committee comprised of representatives of Sanofi-Aventis and Harvard. Projects will be awarded funding based on their scientific merit and potential to generate translational insight and value to biomedical research. The collaboration provides Sanofi-Aventis the opportunity to develop diagnostic, therapeutic and prognostic applications of discoveries made. Complete Story » seekingalpha.com |